Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business

The OTC drug private label giant's share price increased as much as 5% in heavy trading May 31 after the release a day earlier of its complete 2017 first-quarter earnings statement and its announcement of $1.4bn in tender offers for credit notes due starting in 2021.

Business decline

Perrigo Co. PLC's top executives are asserting they are investing in the company’s Rx generic specialty topicals business for the long-term, rather than preparing it for divestment, as some analysts and board members prefer.

Discussion of the fate of the Rx business arose again on May 31 as the company completed its delayed 2017...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip